|
|
| Line 1: |
Line 1: |
| | | | |
| | ==Crystal structure of the AmpC from Pseudomonas aeruginosa with 1C== | | ==Crystal structure of the AmpC from Pseudomonas aeruginosa with 1C== |
| - | <StructureSection load='6i30' size='340' side='right' caption='[[6i30]], [[Resolution|resolution]] 2.21Å' scene=''> | + | <StructureSection load='6i30' size='340' side='right'caption='[[6i30]], [[Resolution|resolution]] 2.21Å' scene=''> |
| | == Structural highlights == | | == Structural highlights == |
| - | <table><tr><td colspan='2'>[[6i30]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/"bacillus_aeruginosus"_(schroeter_1872)_trevisan_1885 "bacillus aeruginosus" (schroeter 1872) trevisan 1885]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6I30 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6I30 FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[6i30]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Pseudomonas_aeruginosa Pseudomonas aeruginosa]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6I30 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6I30 FirstGlance]. <br> |
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=C6S:(3R)-3-(CYCLOHEXYLCARBONYLAMINO)-2-OXIDANYL-3,4-DIHYDRO-1,2-BENZOXABORININE-8-CARBOXYLIC+ACID'>C6S</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.21Å</td></tr> |
| - | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">blaPDC ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=287 "Bacillus aeruginosus" (Schroeter 1872) Trevisan 1885])</td></tr> | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=C6S:(3R)-3-(CYCLOHEXYLCARBONYLAMINO)-2-OXIDANYL-3,4-DIHYDRO-1,2-BENZOXABORININE-8-CARBOXYLIC+ACID'>C6S</scene></td></tr> |
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6i30 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6i30 OCA], [http://pdbe.org/6i30 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6i30 RCSB], [http://www.ebi.ac.uk/pdbsum/6i30 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6i30 ProSAT]</span></td></tr> | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6i30 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6i30 OCA], [https://pdbe.org/6i30 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6i30 RCSB], [https://www.ebi.ac.uk/pdbsum/6i30 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6i30 ProSAT]</span></td></tr> |
| | </table> | | </table> |
| | + | == Function == |
| | + | [https://www.uniprot.org/uniprot/A0A2Z4BUZ1_PSEAI A0A2Z4BUZ1_PSEAI] |
| | <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| | == Publication Abstract from PubMed == | | == Publication Abstract from PubMed == |
| Line 17: |
Line 19: |
| | </div> | | </div> |
| | <div class="pdbe-citations 6i30" style="background-color:#fffaf0;"></div> | | <div class="pdbe-citations 6i30" style="background-color:#fffaf0;"></div> |
| | + | |
| | + | ==See Also== |
| | + | *[[Beta-lactamase 3D structures|Beta-lactamase 3D structures]] |
| | == References == | | == References == |
| | <references/> | | <references/> |
| | __TOC__ | | __TOC__ |
| | </StructureSection> | | </StructureSection> |
| - | [[Category: Brem, J]] | + | [[Category: Large Structures]] |
| - | [[Category: Cahill, S T]] | + | [[Category: Pseudomonas aeruginosa]] |
| - | [[Category: McDonough, M A]] | + | [[Category: Brem J]] |
| - | [[Category: Schofield, C J]]
| + | [[Category: Cahill ST]] |
| - | [[Category: Antibiotic]] | + | [[Category: McDonough MA]] |
| - | [[Category: Antimicrobial resistance]] | + | [[Category: Schofield CJ]] |
| - | [[Category: Beta-lactamase]] | + | |
| - | [[Category: Cyclic boronate]]
| + | |
| - | [[Category: Hydrolase]]
| + | |
| Structural highlights
Function
A0A2Z4BUZ1_PSEAI
Publication Abstract from PubMed
BACKGROUND: The beta-lactam antibiotics represent the most successful drug class for treatment of bacterial infections. Resistance to them, importantly via production of beta-lactamases, which collectively are able to hydrolyse all classes of beta-lactams, threatens their continued widespread use. Bicyclic boronates show potential as broad spectrum inhibitors of the mechanistically distinct serine- (SBL) and metallo- (MBL) beta-lactamase families. METHODS: Using biophysical methods, including crystallographic analysis, we have investigated the binding mode of bicyclic boronates to clinically important beta-lactamases. Induction experiments and agar-based MIC screening against MDR-Enterobacteriaceae (n=132) were used to evaluate induction properties and the in vitro efficacy of a bicyclic boronate in combination with meropenem. RESULTS: Crystallographic analysis of a bicyclic boronate in complex with AmpC from Pseudomonas aeruginosa reveals it binds to form a tetrahedral boronate species. Microbiological studies on the clinical coverage (in combination with meropenem) and induction of beta-lactamases by bicyclic boronates further support the promise of such compounds as broad spectrum beta-lactamase inhibitors. CONCLUSIONS: Together with reported studies on the structural basis of their inhibition of class A, B and D beta-lactamases, biophysical studies, including crystallographic analysis, support the proposal that bicyclic boronates mimic tetrahedral intermediates common to SBL and MBL catalysis. GENERAL SIGNIFICANCE: Bicyclic boronates are a new generation of broad spectrum inhibitors of both SBLs and MBLs.
Studies on the inhibition of AmpC and other beta-lactamases by cyclic boronates.,Cahill ST, Tyrrell JM, Navratilova IH, Calvopina K, Robinson SW, Lohans CT, McDonough MA, Cain R, Fishwick CWG, Avison MB, Walsh TR, Schofield CJ, Brem J Biochim Biophys Acta Gen Subj. 2019 Apr;1863(4):742-748. doi:, 10.1016/j.bbagen.2019.02.004. Epub 2019 Feb 7. PMID:30738906[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
See Also
References
- ↑ Cahill ST, Tyrrell JM, Navratilova IH, Calvopina K, Robinson SW, Lohans CT, McDonough MA, Cain R, Fishwick CWG, Avison MB, Walsh TR, Schofield CJ, Brem J. Studies on the inhibition of AmpC and other beta-lactamases by cyclic boronates. Biochim Biophys Acta Gen Subj. 2019 Apr;1863(4):742-748. doi:, 10.1016/j.bbagen.2019.02.004. Epub 2019 Feb 7. PMID:30738906 doi:http://dx.doi.org/10.1016/j.bbagen.2019.02.004
|
